Company news

Savara, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

March 25, 2025

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

March 25, 2025

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

March 16, 2025

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

March 5, 2025

Savara Announces Participation in the Leerink Global Healthcare Conference

March 2, 2025

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

January 29, 2025

Savara Announces Participation in Upcoming Healthcare Investor Conferences

January 28, 2025

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

December 17, 2024

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

December 16, 2024

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

November 21, 2024

Savara Announces Participation in Upcoming Healthcare Conferences

November 12, 2024

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

November 11, 2024

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

November 3, 2024

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV

October 21, 2024

Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting

September 30, 2024

Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

September 26, 2024

Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

September 23, 2024

Savara to Host Analyst and Investor Webinar on September 30, 2024

September 22, 2024

Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024

September 7, 2024

Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024

August 14, 2024

Savara Reports Second Quarter 2024 Financial Results and Provides Business Update

August 11, 2024

Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock

June 27, 2024

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

June 25, 2024

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

June 24, 2024

Savara to Present at the Jefferies Global Healthcare Conference

May 28, 2024

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

May 18, 2024

Savara Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024

Savara to Present at the Citizens JMP Life Sciences Conference

May 6, 2024

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

April 7, 2024

Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update

March 6, 2024

Savara to Present at the Barclays 26th Annual Global Healthcare Conference

March 5, 2024

Savara to Present at Two Upcoming Healthcare Conferences

January 30, 2024

Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

December 20, 2023

Savara Added to the NASDAQ Biotechnology Index

December 19, 2023

Savara to Present at the Piper Sandler 35th Annual Healthcare Conference

November 20, 2023

Savara Reports Third Quarter Financial Results and Provides Business Update

November 8, 2023

Savara to Present at the Jefferies London Healthcare Conference

November 7, 2023

Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 4, 2023

Savara Reports Second Quarter Financial Results and Provides Business Update

August 9, 2023

Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

July 12, 2023

Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

June 25, 2023

Savara Added to Russell 3000® Index

June 25, 2023

Savara to Present at the Jefferies Healthcare Conference

June 1, 2023

Savara Reports First Quarter Financial Results and Provides Business Update

May 14, 2023

Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update

March 29, 2023

Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 5, 2023

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 27, 2023

Savara Announces New Leadership Appointments

February 13, 2023

Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

November 9, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 65 decks. Every deck is listed under its year.